Isotretinoin (Accutane)

11/01/2023 - "The most effective treatment for acne is isotretinoin, but its usage is associated with a wide range of adverse effects, and regular monitoring is necessary. "
08/01/2023 - "Oral isotretinoin remains the most effective treatment for acne. "
04/17/2023 - "The most effective treatment of acne is isotretinoin and its side effects are for the most part known. "
04/01/2023 - "Systemic isotretinoin is a highly effective treatment for severe and refractory acne but carries risk for serious adverse effects such as teratogenicity. "
10/01/2022 - "Systemic isotretinoin is the most effective treatment for acne vulgaris (AV). "

11/01/2001 - "Because of the clinical and therapeutic implications (impaired quality of life, pigmentation or scarring and remarkable efficacy of oral isotretinoin) this clinical picture merits more attention, and the modalities for the prescription of isotretinoin in this context should be defined."
02/01/2023 - "Concomitant isotretinoin use resulted in a greater ASRE and a significantly greater improvement in icepick scars. "
07/01/2017 - "The opposing studies (challenging common practices; CCP) state that the rate of scarring in isotretinoin patients is low and that delaying elective procedures is unnecessary. "
10/01/2020 - "Patients with concomitant low-dose isotretinoin use reported a further decrease in Scar Global Assessment score (n = 43). "
03/01/2017 - "Common concerns among respondents regarding isotretinoin patients are the risks of poor wound healing and scarring, but the most often reported concern is medicolegal risk (74%). "

02/01/2004 - "The aim of the current study was to assess the toxicity, safety, and efficacy of IFN-alpha combined with isotretinoin in patients with advanced, refractory lymphoid malignancies. "
01/01/2008 - "Our studies using animal model reveled that 13-cis-retinoic acid could significantly (p < 0.001) inhibit the tumor directed capillaries. "
08/01/2007 - "Combination of two differentiation agents such as phenylbutyrate (PB) and 13-cis-retinoic acid (CRA) has been shown to have an additive inhibitory effect on tumor growth in preclinical studies. "
08/01/1992 - "In one recent trial, high-dose 13-cis-retinoic acid treatment resulted in a dramatic reduction in the incidence of second primary tumors. "
04/01/1985 - "In an attempt to increase the peak plasma levels of 13-cis-retinoic acid (13-cis-RA) and its efficacy in vivo, a Phase I study and pharmacokinetics of weekly high-dose, oral 13-cis-RA was conducted in 23 cancer patients who were refractory to conventional treatments. "

12/01/1986 - "At the end of the study period, isotretinoin was found to be highly effective in the clearing of refractory rosacea lesions."
01/01/2021 - "Forty milligrams per week isotretinoin was highly effective for severe rosacea, achieving complete response (over 90% improvement) in 62.5% of patients and partial response (50%-90% improvement) in additional 29.2% of patients. "
02/01/2018 - "Very low-dose isotretinoin (e.g., 10-20 mg once to five times a week, equivalent to 5 mg/day) is an effective treatment for mild to moderate papulopustular rosacea and is well tolerated."
03/05/1982 - "13-cis-retinoic acid was given with good results to 7 patients with exceptionally severe rosacea. "
01/01/2021 - "This study demonstrates that that the use of a weekly low-dose isotretinoin is an effective treatment for papulopustular rosacea, including among patients with severe disease."

12/01/2014 - "Plasma levels of both 13-cRA and 4-oxo-13-cRA should be evaluated in pharmacokinetic studies of isotretinoin in neuroblastoma."
01/01/2022 - "13-cis-Retinoic acid (13-cisRA) is used as a postconsolidation treatment in patients with high-risk neuroblastoma. "
10/01/2021 - "Physeal Abnormalities in Children With High-risk Neuroblastoma Intensively Treated With/Without 13-Cis-Retinoic Acid."
04/14/2021 - "(1) Background: 13-cis-retinoic acid (13-CRA) is a key component of neuroblastoma treatment protocols. "
01/01/2020 - "We report the case of a 9-year-old boy with neuroblastoma who demonstrated premature epiphyseal closure after 1 year of isotretinoin treatment (72.3 mg/m2/day). "